VBL Therapeutics
6 Jonathan Netanyahu Street
Or Yehuda
60376
Tel: 97-236-346450
Fax: 97-236-346449
Website: http://www.vblrx.com/
Email: businessdev@vbl.co.il
209 articles about VBL Therapeutics
-
BioSpace Global Roundup, Sept. 10
9/10/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
VBL Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Clinical Development of VB-601
9/8/2020
VBL Therapeutics (Nasdaq: VBLT) announced today the successful completion of a Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding the Company's development plan for VB-601.
-
VBL Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update
8/13/2020
VBL Therapeutics announced financial results for the second quarter ended June 30, 2020, and provided a corporate update.
-
VBL Therapeutics Announces Second Successful Pre-planned Interim Analysis with a Positive Data Safety Monitoring Committee Review Looking at OS - the Primary Endpoint of the OVAL Phase 3 Potential Registration Study of VB-111 in Ovarian Cancer
8/12/2020
VBL Therapeutics (Nasdaq: VBLT) announced today that the independent Data Safety Monitoring Committee (DSMC) has completed its second, pre-planned interim analysis in the ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111) in patients with platinum-resistant ovarian cancer, and unanimously recommended that the study continue as planned. In this second interim analysis, the DSMC reviewed unblinded Overall Survival (OS)
-
VBL Therapeutics to Report Second Quarter 2020 Financial Results on August 13
8/3/2020
VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, August 13, 2020 at 8:30am Eastern Time to report second quarter ended June 30, 2020 financial results and to provide a corporate update. Thursday, August 13 @ 8:30amET From
-
VBL Therapeutics Presents MOSPD2 Bi-Specific Antibody Activity and Potential Survival Benefit for Solid Tumors in Late Breaking Research Session of the AACR Virtual Annual Meeting
6/22/2020
The company's bi-specific antibody candidates significantly prolonged survival in models of metastatic human cervical and breast cancer
-
Clinical Catch-Up: May 31-June 5
6/8/2020
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look. -
VBL Presents New Data on the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Rheumatoid Arthritis at the EULAR 2020 Congress
6/4/2020
VBL Therapeutics, announced new data implicating the potential of its proprietary anti-MOSPD2 antibodies for treatment of rheumatoid arthritis.
-
VBL Presents Positive Interim Data from the OVAL Phase 3 Pivotal Study in Ovarian Cancer at the ASCO20 Annual Meeting, Showing 58% or Higher Objective Response Rate
6/1/2020
OVAL independent Data Safety Monitoring Committee (DSMC) reviewed un-blinded data and determined that the study has met the interim pre-specified criterion of an absolute percentage advantage of 10% or higher in CA-125 response in the VB-111 treated arm compared to control. The DSMC recommended that the study proceed without modification.
-
The American Society of Clinical Oncology 2020 meeting was held virtually this year due to the COVID-19 pandemic. As usual, there were literally hundreds of abstracts, posters and presentations. Here’s a look at some of the highlights.
-
VBL Therapeutics to Present New Data on Its MOSPD2 Bispecific Antibody Program for Solid Tumors in Late Breaking Research Session of the AACR Virtual Annual Meeting
5/18/2020
New data provide proof-of-concept for VBL's proprietary MOSPD2 bi-specific antibodies, observing survival benefit and no evidence of toxicity in a model of metastatic human cervical cancer
-
VBL Therapeutics Announces First Quarter 2020 Financial Results and Provides Corporate UpdateConference Call and Webcast at 8:30am Eastern Time Today
5/14/2020
VBL Therapeutics announced financial results for the first quarter ended March 31, 2020, and provided a corporate update.
-
VBL Therapeutics Closes $8.1 Million Registered Direct Offering to Key Current Shareholders Priced At-the-Market under Nasdaq RulesRaised $18.1 Million of Gross Proceeds in Two Registered Direct Offerings
5/13/2020
VBL Therapeutics (Nasdaq: VBLT), today announced that it has closed the previously announced offering of 5,142,857 ordinary shares of the Company, at a purchase price of $1.575 per share, in a registered direct offering priced at-the-market under Nasdaq rules
-
VBL Therapeutics Closes $10.0 Million Registered Direct Offering and Announces $8.1 Million Registered Direct Offering to Key Current Shareholders, Each Priced At-the-Market under Nasdaq Rules
5/12/2020
VBL Therapeutics (Nasdaq: VBLT), today announced that it has closed the previously announced registered direct offering of 6,349,208 ordinary shares of the Company, at a purchase price of $1.575 per share, in a registered direct offering priced at-the-market under Nasdaq rules. VBL has also issued to the investors, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 6,349,208 of VBL’s ordinary shares. The
-
VBL Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
5/7/2020
VBL Therapeutics (Nasdaq: VBLT), today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of 6,349,208 ordinary shares of the Company, at a purchase price of $1.575 per share, in a registered direct offering priced at-the-market under Nasdaq rules. VBL has also agreed to issue to the investors, in a concurrent private placement, unregistered warrants to purchase up to an aggr
-
VBL Presents New Data on MOSPD2 Antibodies as Potential Treatment for NASH and Colitis at DDW
5/6/2020
Study was rated in the top 10% of all abstracts in this category and was selected as Poster of Distinction
-
VBL Therapeutics to Report First Quarter 2020 Financial Results on May 14
5/4/2020
VBL Therapeutics announced that it will host a conference call and live audio webcast on Thursday, May 14, 2020 at 8:30am Eastern Time to report first quarter ended March 31, 2020 financial results and to provide a corporate update.
-
VBL First-in-class MOSPD2 Antibodies Show Potential for Treatment for CNS InflammationData were published in a peer-review manuscript in Clinical & Experimental Immunology
5/4/2020
VBL Therapeutics is pleased to announce the publication of a new manuscript demonstrating the potential of MOSPD2 antibodies for Multiple Sclerosis.
-
VBL Therapeutics Awarded 3.2 Million NIS Non-Dilutive Grant by the Israel Innovation Authority for VB-111
4/21/2020
VBL Therapeutics (Nasdaq: VBLT) today announced that it has been awarded a non-dilutive grant of up to 3.175 million New Israeli Shekels (NIS) (approximately $0.9 million) by the Israel Innovation Authority (IIA). The IIA has approved a budget of approximately $1.8 million for the VB-111 project during 2020, with 50% of this amount as an IIA grant. The funds will support the continued development of VBL's lead product candidate, VB-111, a fi
-
VBL Therapeutics Announces New Milestone Event in the VB-201 Collaboration for Veterinary Use
4/6/2020
VBL Therapeutics, announced that it has reached a milestone event under its collaborative agreement with a world-leading European animal health company, evaluating use of VB-201 for veterinary applications.